{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-07-11T06:01:17.740004+00:00","company":{"ticker":"ZBH","cik":1136869,"company_name":"ZIMMER BIOMET HOLDINGS, INC."},"pagination":{"limit":100,"returned":58,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","counterparties":{"contract_counterparty":[{"display_name":"JPMorgan Chase Bank, N.A.","detail":"credit_facility","count":4,"first_seen":"2023-07-10T23:59:59+00:00","last_seen":"2023-07-10T23:59:59+00:00","evidence_fact_ids":[132849,132850,132851,132852]},{"display_name":"Barclays Capital Inc., Goldman Sachs & Co. LLC, Mizuho Securities USA LLC and Morgan Stanley & Co. LLC","detail":"underwriting","count":1,"first_seen":"2023-12-01T23:59:59+00:00","last_seen":"2023-12-01T23:59:59+00:00","evidence_fact_ids":[90540]},{"display_name":"Computershare Trust Company, N.A.","detail":"notes_offering","count":1,"first_seen":"2023-12-01T23:59:59+00:00","last_seen":"2023-12-01T23:59:59+00:00","evidence_fact_ids":[90541]}],"lender":[{"display_name":"JPMorgan Chase Bank, N.A.","detail":"revolving_credit","count":4,"first_seen":"2023-07-10T23:59:59+00:00","last_seen":"2025-06-30T23:59:59+00:00","evidence_fact_ids":[44766,44767,132854,132855]},{"display_name":"noteholders","detail":"senior_notes","count":3,"first_seen":"2025-02-19T23:59:59+00:00","last_seen":"2025-02-19T23:59:59+00:00","evidence_fact_ids":[144558,144559,144560]},{"display_name":"Barclays Capital Inc., Goldman Sachs & Co. LLC, Mizuho Securities USA LLC and Morgan Stanley & Co. LLC","detail":"senior_notes","count":1,"first_seen":"2023-12-01T23:59:59+00:00","last_seen":"2023-12-01T23:59:59+00:00","evidence_fact_ids":[90545]}]},"facts":[{"fact_type":"shareholder_vote","fact_key":"789e57ab557967caeb9381bdc688096425be6713","cik":1136869,"ticker":"ZBH","company_name":"ZIMMER BIOMET HOLDINGS, INC.","filed_at":"2026-05-27T21:30:16+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-05-22","outcome":"failed","proposal_text":"Shareholder proposal on Independent Board Chairman","proposal_type":"other","results":[{"broker_non_votes":"12,009,707","subject":null,"votes_abstain":"-","votes_against":"137,043,058","votes_for":"31,288,886","votes_withheld":null}]},"claim":"ZIMMER BIOMET HOLDINGS, INC. shareholders rejected Shareholder proposal on Independent Board Chairman at the 2026-05-22 meeting.","evidence_excerpt":"• rejected a shareholder proposal on Independent Board Chairman (Proposal 4).","confidence":0.99,"filing_url":"https://secwatch.observer/filing/0001193125-26-242207","anchor_url":"https://secwatch.observer/filing/0001193125-26-242207#claim-789e57ab557967caeb9381bdc688096425be6713","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1136869/000119312526242207/0001193125-26-242207-index.htm"},{"fact_type":"shareholder_vote","fact_key":"630ecd04fa57b5c951eff4b4158b83fa5b46f5cc","cik":1136869,"ticker":"ZBH","company_name":"ZIMMER BIOMET HOLDINGS, INC.","filed_at":"2026-05-27T21:30:16+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-05-22","outcome":"passed","proposal_text":"Advisory vote to approve named executive officer compensation","proposal_type":"say_on_pay","results":[{"broker_non_votes":"12,009,707","subject":null,"votes_abstain":"273,703","votes_against":"8,386,847","votes_for":"160,066,066","votes_withheld":null}]},"claim":"ZIMMER BIOMET HOLDINGS, INC. shareholders approved Advisory vote to approve named executive officer compensation at the 2026-05-22 meeting.","evidence_excerpt":"• approved, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Company’s proxy statement (Proposal 3);","confidence":0.99,"filing_url":"https://secwatch.observer/filing/0001193125-26-242207","anchor_url":"https://secwatch.observer/filing/0001193125-26-242207#claim-630ecd04fa57b5c951eff4b4158b83fa5b46f5cc","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1136869/000119312526242207/0001193125-26-242207-index.htm"},{"fact_type":"shareholder_vote","fact_key":"d0a4baabe9831c99960f0a4cd3710a45c2d60b0d","cik":1136869,"ticker":"ZBH","company_name":"ZIMMER BIOMET HOLDINGS, INC.","filed_at":"2026-05-27T21:30:16+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-05-22","outcome":"passed","proposal_text":"Ratification of the Audit Committee’s appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for 2026","proposal_type":"auditor_ratification","results":[{"broker_non_votes":"0","subject":null,"votes_abstain":"110,176","votes_against":"7,887,786","votes_for":"172,738,361","votes_withheld":null}]},"claim":"ZIMMER BIOMET HOLDINGS, INC. shareholders approved Ratification of the Audit Committee’s appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for 2026 at the 2026-05-22 meeting.","evidence_excerpt":"• ratified the Audit Committee’s appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for 2026 (Proposal 2);","confidence":0.99,"filing_url":"https://secwatch.observer/filing/0001193125-26-242207","anchor_url":"https://secwatch.observer/filing/0001193125-26-242207#claim-d0a4baabe9831c99960f0a4cd3710a45c2d60b0d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1136869/000119312526242207/0001193125-26-242207-index.htm"},{"fact_type":"shareholder_vote","fact_key":"4bb6bb78f6b1a7328251da3084116c8a6a003049","cik":1136869,"ticker":"ZBH","company_name":"ZIMMER BIOMET HOLDINGS, INC.","filed_at":"2026-05-27T21:30:16+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-05-22","outcome":"passed","proposal_text":"Election of ten directors for one-year terms ending at the 2027 annual meeting","proposal_type":"director_election","results":[{"broker_non_votes":"12,009,707","subject":"Betsy J. Bernard","votes_abstain":"92,412","votes_against":"6,060,594","votes_for":"162,573,610","votes_withheld":null},{"broker_non_votes":"12,009,707","subject":"Michael J. Farrell","votes_abstain":"99,711","votes_against":"4,180,484","votes_for":"164,446,421","votes_withheld":null},{"broker_non_votes":"12,009,707","subject":"Robert A. Hagemann","votes_abstain":"101,995","votes_against":"6,126,364","votes_for":"162,498,257","votes_withheld":null},{"broker_non_votes":"12,009,707","subject":"Arthur J. Higgins","votes_abstain":"101,087","votes_against":"4,236,047","votes_for":"164,389,482","votes_withheld":null},{"broker_non_votes":"12,009,707","subject":"Maria Teresa Hilado","votes_abstain":"189,990","votes_against":"4,797,047","votes_for":"163,739,579","votes_withheld":null},{"broker_non_votes":"12,009,707","subject":"Syed Jafry","votes_abstain":"105,713","votes_against":"2,648,596","votes_for":"165,972,307","votes_withheld":null},{"broker_non_votes":"12,009,707","subject":"Sreelakshmi Kolli","votes_abstain":"102,476","votes_against":"1,734,443","votes_for":"166,889,697","votes_withheld":null},{"broker_non_votes":"12,009,707","subject":"Devdatt Kurdikar","votes_abstain":"202,415","votes_against":"7,634,226","votes_for":"160,889,975","votes_withheld":null},{"broker_non_votes":"12,009,707","subject":"Louis A. Shapiro","votes_abstain":"101,967","votes_against":"1,110,244","votes_for":"167,514,405","votes_withheld":null},{"broker_non_votes":"12,009,707","subject":"Ivan Tornos","votes_abstain":"533,020","votes_against":"5,540,638","votes_for":"162,652,958","votes_withheld":null}]},"claim":"ZIMMER BIOMET HOLDINGS, INC. shareholders approved Election of ten directors for one-year terms ending at the 2027 annual meeting at the 2026-05-22 meeting.","evidence_excerpt":"• elected ten (10) directors for one-year terms ending at the 2027 annual meeting of shareholders (Proposal 1);","confidence":0.99,"filing_url":"https://secwatch.observer/filing/0001193125-26-242207","anchor_url":"https://secwatch.observer/filing/0001193125-26-242207#claim-4bb6bb78f6b1a7328251da3084116c8a6a003049","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1136869/000119312526242207/0001193125-26-242207-index.htm"},{"fact_type":"earnings_release","fact_key":"66c328cc5bacf934b44ceada1e037cd24723ad37","cik":1136869,"ticker":"ZBH","company_name":"ZIMMER BIOMET HOLDINGS, INC.","filed_at":"2026-04-28T23:59:59+00:00","payload":{"eps_text":"$8.40 - $8.55","guidance_signal":"raised","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the fiscal year ending December 31, 2026","report_date":"2026-04-28","result_type":"guidance_update","revenue_text":null},"claim":"ZIMMER BIOMET HOLDINGS, INC. reported the fiscal year ending December 31, 2026 results: EPS $8.40 - $8.55. Guidance raised.","evidence_excerpt":"The Company is updating its full-year 2026 financial guidance as follows:","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-183411","anchor_url":"https://secwatch.observer/filing/0001193125-26-183411#claim-66c328cc5bacf934b44ceada1e037cd24723ad37","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1136869/000119312526183411/0001193125-26-183411-index.htm"},{"fact_type":"earnings_release","fact_key":"bf17dbc8685784e0c83fdd46dbad9e5615437d8b","cik":1136869,"ticker":"ZBH","company_name":"ZIMMER BIOMET HOLDINGS, INC.","filed_at":"2026-04-28T23:59:59+00:00","payload":{"eps_text":"$1.22","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$238.1 million","period_text":"the quarter ended March 31, 2026","report_date":"2026-04-28","result_type":"reported_results","revenue_text":"$2.087 billion"},"claim":"ZIMMER BIOMET HOLDINGS, INC. reported the quarter ended March 31, 2026 results: revenue $2.087 billion, net income $238.1 million, EPS $1.22.","evidence_excerpt":"The Company reported first quarter net sales of $2.087 billion, an increase of 9.3% over the prior year period, an increase of 6.8% on a constant currency 1 basis and an increase of 2.9% on an organic constant currency 1 basis.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-183411","anchor_url":"https://secwatch.observer/filing/0001193125-26-183411#claim-bf17dbc8685784e0c83fdd46dbad9e5615437d8b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1136869/000119312526183411/0001193125-26-183411-index.htm"},{"fact_type":"executive_change","fact_key":"d008e49b58","cik":1136869,"ticker":"ZBH","company_name":"ZIMMER BIOMET HOLDINGS, INC.","filed_at":"2026-04-28T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2026-04-28","interim":true,"role":"interim Chief Financial Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Paul Stellato was appointed as interim Chief Financial Officer at ZIMMER BIOMET HOLDINGS, INC..","evidence_excerpt":"Paul Stellato, Vice President, Controller and Chief Accounting Officer, has been appointed to act, along with continuing to serve in his current role, as the Company’s interim Chief Financial Officer, effective upon Mr. Upadhyay’s departure, until a permanent successor is named.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-26-183430","anchor_url":"https://secwatch.observer/filing/0001193125-26-183430#claim-d008e49b58","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1136869/000119312526183430/0001193125-26-183430-index.htm"},{"fact_type":"executive_change","fact_key":"19db2f8d7b","cik":1136869,"ticker":"ZBH","company_name":"ZIMMER BIOMET HOLDINGS, INC.","filed_at":"2026-04-28T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2026-04-28","interim":false,"role":"Chief Financial Officer and Executive Vice President – Finance, Operations and Supply Chain","role_category":"cfo","successor_name":"Paul Stellato","successor_named":true},"claim":"Suketu Upadhyay resigned as Chief Financial Officer and Executive Vice President – Finance, Operations and Supply Chain at ZIMMER BIOMET HOLDINGS, INC..","evidence_excerpt":"On April 22, 2026, Suketu Upadhyay informed Zimmer Biomet Holdings, Inc. (the “Company”) of his intention to resign from the position of Chief Financial Officer and Executive Vice President – Finance, Operations and Supply Chain of the Company, effective as of April 28, 2026, to pursue a new professional opportunity.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-26-183430","anchor_url":"https://secwatch.observer/filing/0001193125-26-183430#claim-19db2f8d7b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1136869/000119312526183430/0001193125-26-183430-index.htm"},{"fact_type":"debt_financing","fact_key":"d1354c6654bb124c038302266ba9c98d5dbe7e00","cik":1136869,"ticker":"ZBH","company_name":"ZIMMER BIOMET HOLDINGS, INC.","filed_at":"2025-06-30T23:59:59+00:00","payload":{"counterparty":"JPMorgan Chase Bank, N.A.","effective_date":"2025-06-27","event":"incurrence","instrument_type":"revolving_credit","interest_rate_text":"floating rates based upon either an adjusted Term SOFR for the applicable intere","item_codes_triggered":["2.03"],"maturity_text":"June 26, 2026","principal_text":"$1.0 billion"},"claim":"ZIMMER BIOMET HOLDINGS, INC. incurred revolving credit of $1.0 billion with JPMorgan Chase Bank, N.A. at floating rates based upon either an adjusted Term SOFR for the applicable intere maturing June 26, 2026.","evidence_excerpt":"The 364-Day Revolving Credit Agreement, dated as of June 27, 2025, among the Company, the lenders party thereto and JPMorgan Chase Bank, N.A., as administrative agent (the “364-Day Credit Agreement”), is an unsecured revolving credit facility in the principal amount of $1.0 billion (the “364-Day Revolving Facility”).","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-25-152694","anchor_url":"https://secwatch.observer/filing/0001193125-25-152694#claim-d1354c6654bb124c038302266ba9c98d5dbe7e00","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1136869/000119312525152694/0001193125-25-152694-index.htm"},{"fact_type":"debt_financing","fact_key":"db3a5e8323f273e95dd4014135542c21771efa2e","cik":1136869,"ticker":"ZBH","company_name":"ZIMMER BIOMET HOLDINGS, INC.","filed_at":"2025-06-30T23:59:59+00:00","payload":{"counterparty":"JPMorgan Chase Bank, N.A.","effective_date":"2025-06-27","event":"incurrence","instrument_type":"revolving_credit","interest_rate_text":"floating rates based upon either an adjusted Term SOFR for the applicable intere","item_codes_triggered":["2.03"],"maturity_text":"June 27, 2030","principal_text":"$1.5 billion"},"claim":"ZIMMER BIOMET HOLDINGS, INC. incurred revolving credit of $1.5 billion with JPMorgan Chase Bank, N.A. at floating rates based upon either an adjusted Term SOFR for the applicable intere maturing June 27, 2030.","evidence_excerpt":"the Company, the lenders party thereto and JPMorgan Chase Bank, N.A., as administrative agent (the “Five-Year Credit Agreement”), is a five-year unsecured revolving facility of $1.5 billion (the “Five-Year Revolving Facility”). The Five-Year Credit Agreement will mature on June 27, 2030, with two one-year extensions exercisable at the Company’s discretion and","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-25-152694","anchor_url":"https://secwatch.observer/filing/0001193125-25-152694#claim-db3a5e8323f273e95dd4014135542c21771efa2e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1136869/000119312525152694/0001193125-25-152694-index.htm"},{"fact_type":"governance_change","fact_key":"fd2928bb6c7cee252eb1070b47f384f70c5b3055","cik":1136869,"ticker":"ZBH","company_name":"ZIMMER BIOMET HOLDINGS, INC.","filed_at":"2025-06-03T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2025-05-29","item_codes_triggered":["5.03"],"summary_text":"Amended Restated Certificate of Incorporation to limit personal liability of certain officers for monetary damages for breach of duty of care as permitted under Delaware law."},"claim":"ZIMMER BIOMET HOLDINGS, INC.: Amended Restated Certificate of Incorporation to limit personal liability of certain officers for monetary damages for breach of duty of care as permitted under Delaware law (effective 2025-05-29).","evidence_excerpt":"At the Annual Meeting, the Company’s shareholders approved an amendment (the “Amendment”) to the Company’s Restated Certificate of Incorporation (the “Charter”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-25-080567","anchor_url":"https://secwatch.observer/filing/0000950170-25-080567#claim-fd2928bb6c7cee252eb1070b47f384f70c5b3055","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1136869/000095017025080567/0000950170-25-080567-index.htm"},{"fact_type":"executive_change","fact_key":"95978a97ae","cik":1136869,"ticker":"ZBH","company_name":"ZIMMER BIOMET HOLDINGS, INC.","filed_at":"2025-05-27T23:59:59+00:00","payload":{"action":"ceased to be an executive officer","action_category":"departure","departure_tone":"routine","effective_date":"2025-07-01","interim":false,"role":"President, Americas","role_category":"president","successor_name":null,"successor_named":false},"claim":"Mark Bezjak departed as President, Americas at ZIMMER BIOMET HOLDINGS, INC..","evidence_excerpt":"Mark Bezjak, President, Americas, will continue to hold such office but will cease to be an executive officer of the Company at the time Mr. Thornal joins the Company.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-25-126231","anchor_url":"https://secwatch.observer/filing/0001193125-25-126231#claim-95978a97ae","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1136869/000119312525126231/0001193125-25-126231-index.htm"},{"fact_type":"executive_change","fact_key":"8a82f18de0","cik":1136869,"ticker":"ZBH","company_name":"ZIMMER BIOMET HOLDINGS, INC.","filed_at":"2025-05-27T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-07-01","interim":false,"role":"Group President, Global Businesses and the Americas","role_category":"president","successor_name":null,"successor_named":false},"claim":"Kevin Thornal was appointed as Group President, Global Businesses and the Americas at ZIMMER BIOMET HOLDINGS, INC..","evidence_excerpt":"Kevin Thornal has been appointed to the newly-created position of Group President, Global Businesses and the Americas of the Company, effective July 1, 2025.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-25-126231","anchor_url":"https://secwatch.observer/filing/0001193125-25-126231#claim-8a82f18de0","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1136869/000119312525126231/0001193125-25-126231-index.htm"},{"fact_type":"executive_change","fact_key":"73e6698cae","cik":1136869,"ticker":"ZBH","company_name":"ZIMMER BIOMET HOLDINGS, INC.","filed_at":"2025-02-25T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-05-29","interim":false,"role":"Lead Independent Director","role_category":"other","successor_name":null,"successor_named":false},"claim":"Michael Farrell was appointed as Lead Independent Director at ZIMMER BIOMET HOLDINGS, INC..","evidence_excerpt":"has appointed Michael Farrell to be the Lead Independent Director of the Board, effective upon the commencement of Mr. Tornos’ service as Chairman.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-25-035147","anchor_url":"https://secwatch.observer/filing/0001193125-25-035147#claim-73e6698cae","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1136869/000119312525035147/0001193125-25-035147-index.htm"},{"fact_type":"executive_change","fact_key":"2165a984e0","cik":1136869,"ticker":"ZBH","company_name":"ZIMMER BIOMET HOLDINGS, INC.","filed_at":"2025-02-25T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-05-29","interim":false,"role":"Chairman of the Board","role_category":"chair","successor_name":null,"successor_named":false},"claim":"Ivan Tornos was appointed as Chairman of the Board at ZIMMER BIOMET HOLDINGS, INC..","evidence_excerpt":"has appointed Ivan Tornos, the Company’s President, Chief Executive Officer and a director, as the Chairman of the Board, effective on May 29, 2025","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-25-035147","anchor_url":"https://secwatch.observer/filing/0001193125-25-035147#claim-2165a984e0","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1136869/000119312525035147/0001193125-25-035147-index.htm"},{"fact_type":"executive_change","fact_key":"6a082db479","cik":1136869,"ticker":"ZBH","company_name":"ZIMMER BIOMET HOLDINGS, INC.","filed_at":"2025-02-25T23:59:59+00:00","payload":{"action":"will retire","action_category":"departure","departure_tone":"retirement","effective_date":"2025-05-29","interim":false,"role":"Chairman of the Board","role_category":"chair","successor_name":"Ivan Tornos","successor_named":true},"claim":"Christopher Begley departed as Chairman of the Board at ZIMMER BIOMET HOLDINGS, INC..","evidence_excerpt":"Christopher Begley, the Company’s Chairman of the Board, is not eligible for nomination by the Board for election as a director at the 2025 Annual Meeting and will retire from the Board when his current term expires at such meeting.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-25-035147","anchor_url":"https://secwatch.observer/filing/0001193125-25-035147#claim-6a082db479","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1136869/000119312525035147/0001193125-25-035147-index.htm"},{"fact_type":"debt_financing","fact_key":"5e3824d18448a754b109024fae0b5dd52bd7c903","cik":1136869,"ticker":"ZBH","company_name":"ZIMMER BIOMET HOLDINGS, INC.","filed_at":"2025-02-19T23:59:59+00:00","payload":{"counterparty":"noteholders","effective_date":"2025-02-19","event":"incurrence","instrument_type":"senior_notes","interest_rate_text":"5.500%","item_codes_triggered":["2.03"],"maturity_text":"February 19, 2035","principal_text":"$600,000,000"},"claim":"ZIMMER BIOMET HOLDINGS, INC. incurred senior notes of $600,000,000 with noteholders at 5.500% maturing February 19, 2035.","evidence_excerpt":"On February 19, 2025, Zimmer Biomet Holdings, Inc. (the “Company”) completed its previously announced issuance of $600,000,000 aggregate principal amount of its 4.700% notes due 2027 (the “2027 Notes”), $550,000,000 aggregate principal amount of its 5.050% notes due 2030 (the “2030 Notes”) and $600,000,000 aggregate principal amount of its 5.500% notes due 2035 (the “2035 Notes” and, together with the 2027 Notes and the 2030 Notes, the “Notes”).","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-25-029614","anchor_url":"https://secwatch.observer/filing/0001193125-25-029614#claim-5e3824d18448a754b109024fae0b5dd52bd7c903","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1136869/000119312525029614/0001193125-25-029614-index.htm"},{"fact_type":"debt_financing","fact_key":"9daad87bc9f6c82dfdfd703956cef2124c02e12c","cik":1136869,"ticker":"ZBH","company_name":"ZIMMER BIOMET HOLDINGS, INC.","filed_at":"2025-02-19T23:59:59+00:00","payload":{"counterparty":"noteholders","effective_date":"2025-02-19","event":"incurrence","instrument_type":"senior_notes","interest_rate_text":"5.050%","item_codes_triggered":["2.03"],"maturity_text":"February 19, 2030","principal_text":"$550,000,000"},"claim":"ZIMMER BIOMET HOLDINGS, INC. incurred senior notes of $550,000,000 with noteholders at 5.050% maturing February 19, 2030.","evidence_excerpt":"On February 19, 2025, Zimmer Biomet Holdings, Inc. (the “Company”) completed its previously announced issuance of $600,000,000 aggregate principal amount of its 4.700% notes due 2027 (the “2027 Notes”), $550,000,000 aggregate principal amount of its 5.050% notes due 2030 (the “2030 Notes”) and $600,000,000 aggregate principal amount of its 5.500% notes due 2035 (the “2035 Notes” and, together with the 2027 Notes and the 2030 Notes, the “Notes”).","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-25-029614","anchor_url":"https://secwatch.observer/filing/0001193125-25-029614#claim-9daad87bc9f6c82dfdfd703956cef2124c02e12c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1136869/000119312525029614/0001193125-25-029614-index.htm"},{"fact_type":"debt_financing","fact_key":"75414ab24140b6e5fa9032abab5e9b0bb2937dea","cik":1136869,"ticker":"ZBH","company_name":"ZIMMER BIOMET HOLDINGS, INC.","filed_at":"2025-02-19T23:59:59+00:00","payload":{"counterparty":"noteholders","effective_date":"2025-02-19","event":"incurrence","instrument_type":"senior_notes","interest_rate_text":"4.700%","item_codes_triggered":["2.03"],"maturity_text":"February 19, 2027","principal_text":"$600,000,000"},"claim":"ZIMMER BIOMET HOLDINGS, INC. incurred senior notes of $600,000,000 with noteholders at 4.700% maturing February 19, 2027.","evidence_excerpt":"On February 19, 2025, Zimmer Biomet Holdings, Inc. (the “Company”) completed its previously announced issuance of $600,000,000 aggregate principal amount of its 4.700% notes due 2027 (the “2027 Notes”), $550,000,000 aggregate principal amount of its 5.050% notes due 2030 (the “2030 Notes”) and $600,000,000 aggregate principal amount of its 5.500% notes due 2035 (the “2035 Notes” and, together with the 2027 Notes and the 2030 Notes, the “Notes”).","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-25-029614","anchor_url":"https://secwatch.observer/filing/0001193125-25-029614#claim-75414ab24140b6e5fa9032abab5e9b0bb2937dea","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1136869/000119312525029614/0001193125-25-029614-index.htm"},{"fact_type":"executive_change","fact_key":"aedf0ddc4b","cik":1136869,"ticker":"ZBH","company_name":"ZIMMER BIOMET HOLDINGS, INC.","filed_at":"2024-06-20T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-06-20","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Devdatt Kurdikar was appointed as Director at ZIMMER BIOMET HOLDINGS, INC..","evidence_excerpt":"On June 20, 2024, the Board of Directors (the “Board”) of Zimmer Biomet Holdings, Inc. (the “Company”), upon the recommendation of the Corporate Governance Committee, increased the size of the Board from ten members to eleven members and appointed Devdatt Kurdikar to fill the resulting vacancy","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0000950170-24-075310","anchor_url":"https://secwatch.observer/filing/0000950170-24-075310#claim-aedf0ddc4b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1136869/000095017024075310/0000950170-24-075310-index.htm"},{"fact_type":"shareholder_vote","fact_key":"36a27366986b294fdcf0d32dc5a1390fd0a1ef20","cik":1136869,"ticker":"ZBH","company_name":"ZIMMER BIOMET HOLDINGS, INC.","filed_at":"2024-05-15T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-05-10","outcome":"passed","proposal_text":"Approval of the Amended Employee Stock Purchase Plan","proposal_type":"equity_plan","votes_abstain_text":"178,037","votes_against_text":"603,453","votes_for_text":"171,503,181"},"claim":"ZIMMER BIOMET HOLDINGS, INC. shareholders approved Approval of the Amended Employee Stock Purchase Plan at the 2024-05-10 meeting.","evidence_excerpt":"Proposal 4 – Approval of the Amended Employee Stock Purchase Plan For Against Abstain Broker Non-Votes 171,503,181 603,453 178,037 14,430,099","confidence":0.99,"filing_url":"https://secwatch.observer/filing/0000950170-24-060580","anchor_url":"https://secwatch.observer/filing/0000950170-24-060580#claim-36a27366986b294fdcf0d32dc5a1390fd0a1ef20","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1136869/000095017024060580/0000950170-24-060580-index.htm"},{"fact_type":"shareholder_vote","fact_key":"30e83c833cee0401da117bd574f77d57b2cb36d6","cik":1136869,"ticker":"ZBH","company_name":"ZIMMER BIOMET HOLDINGS, INC.","filed_at":"2024-05-15T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-05-10","outcome":"passed","proposal_text":"Advisory Vote to Approve Named Executive Officer Compensation","proposal_type":"say_on_pay","votes_abstain_text":"239,816","votes_against_text":"15,603,941","votes_for_text":"156,440,914"},"claim":"ZIMMER BIOMET HOLDINGS, INC. shareholders approved Advisory Vote to Approve Named Executive Officer Compensation at the 2024-05-10 meeting.","evidence_excerpt":"Proposal 3 – Advisory Vote to Approve Named Executive Officer Compensation For Against Abstain Broker Non-Votes 156,440,914 15,603,941 239,816 14,430,099","confidence":0.99,"filing_url":"https://secwatch.observer/filing/0000950170-24-060580","anchor_url":"https://secwatch.observer/filing/0000950170-24-060580#claim-30e83c833cee0401da117bd574f77d57b2cb36d6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1136869/000095017024060580/0000950170-24-060580-index.htm"},{"fact_type":"shareholder_vote","fact_key":"c456a814479dd332ebe03cf86f173f3ccb3b40cd","cik":1136869,"ticker":"ZBH","company_name":"ZIMMER BIOMET HOLDINGS, INC.","filed_at":"2024-05-15T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-05-10","outcome":"passed","proposal_text":"Ratification of the Appointment of the Independent Registered Public Accounting Firm","proposal_type":"auditor_ratification","votes_abstain_text":"157,574","votes_against_text":"6,535,348","votes_for_text":"180,021,848"},"claim":"ZIMMER BIOMET HOLDINGS, INC. shareholders approved Ratification of the Appointment of the Independent Registered Public Accounting Firm at the 2024-05-10 meeting.","evidence_excerpt":"Proposal 2 – Ratification of the Appointment of the Independent Registered Public Accounting Firm For Against Abstain Broker Non-Votes 180,021,848 6,535,348 157,574 0","confidence":0.99,"filing_url":"https://secwatch.observer/filing/0000950170-24-060580","anchor_url":"https://secwatch.observer/filing/0000950170-24-060580#claim-c456a814479dd332ebe03cf86f173f3ccb3b40cd","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1136869/000095017024060580/0000950170-24-060580-index.htm"},{"fact_type":"shareholder_vote","fact_key":"5a5c158cdc20803e3863b4fa0235f3f6902b94ce","cik":1136869,"ticker":"ZBH","company_name":"ZIMMER BIOMET HOLDINGS, INC.","filed_at":"2024-05-15T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-05-10","outcome":"passed","proposal_text":"Election of Directors","proposal_type":"director_election","votes_abstain_text":"N/A (slate)","votes_against_text":"N/A (slate)","votes_for_text":"N/A (slate, see individual nominee tallies)"},"claim":"ZIMMER BIOMET HOLDINGS, INC. shareholders approved Election of Directors at the 2024-05-10 meeting.","evidence_excerpt":"Proposal 1 – Election of Directors Nominee For Against Abstain Broker Non-Votes Christopher B. Begley 164,724,972 7,333,022 226,677 14,430,099 Betsy J. Bernard 162,760,822 9,396,081 127,768 14,430,099 Michael J. Farrell 167,518,122 4,633,274 133,275 14,430,099 Robert A. Hagemann 162,464,750 9,591,079 228,842 14,430,099 Arthur J. Higgins 166,306,021 5,846,729 131,921 14,430,099 Maria Teresa Hilado 169,774,488 2,389,765 120,418 14,430,099 Syed Jafry 170,362,310 1,786,113 136,248 14,430,099 Sreelakshmi Kolli 162,271,545 9,878,950 134,176 14,430,099 Louis Shapiro 171,579,592 573,252 131,827 14,430,099 Ivan Tornos 169,580,110 2,565,650 138,911 14,430,099","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-24-060580","anchor_url":"https://secwatch.observer/filing/0000950170-24-060580#claim-5a5c158cdc20803e3863b4fa0235f3f6902b94ce","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1136869/000095017024060580/0000950170-24-060580-index.htm"},{"fact_type":"earnings_release","fact_key":"2d089881f0adedb967c22378ddfaba2b005eebef","cik":1136869,"ticker":"ZBH","company_name":"ZIMMER BIOMET HOLDINGS, INC.","filed_at":"2024-05-02T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"full-year 2024","report_date":"2024-05-02","result_type":"guidance_update","revenue_text":null},"claim":"ZIMMER BIOMET HOLDINGS, INC. updated its full-year 2024 guidance (reaffirmed).","evidence_excerpt":"The Company is reiterating its current full-year 2024 financial guidance. Projected Year Ending December 31, 2024 2024 Reported Revenue Change 4.5% - 5.5% Foreign Currency Exchange Impact (0.5)% 2024 Constant Currency Revenue Change 5.0% - 6.0% Adjusted Diluted EPS (1) $8.00 - $8.15","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-24-051551","anchor_url":"https://secwatch.observer/filing/0000950170-24-051551#claim-2d089881f0adedb967c22378ddfaba2b005eebef","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1136869/000095017024051551/0000950170-24-051551-index.htm"},{"fact_type":"earnings_release","fact_key":"95667f662e27ea0ac28078c273e3fe0661ee0464","cik":1136869,"ticker":"ZBH","company_name":"ZIMMER BIOMET HOLDINGS, INC.","filed_at":"2024-05-02T23:59:59+00:00","payload":{"eps_text":"$0.84","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$172.4 million","period_text":"quarter ended March 31, 2024","report_date":"2024-05-02","result_type":"reported_results","revenue_text":"$1.889 billion"},"claim":"ZIMMER BIOMET HOLDINGS, INC. reported quarter ended March 31, 2024 results: revenue $1.889 billion, net income $172.4 million, EPS $0.84.","evidence_excerpt":"The Company reported first quarter net sales of $1.889 billion, an increase of 3.2% over the prior year period, and an increase of 4.4% on a constant currency 1 basis. Net earnings for the first quarter were $172.4 million, or $399.7 million on an adjusted 1 basis. Diluted earnings per share were $0.84 for the first quarter, and adjusted 1 diluted earnings per share were $1.94.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-24-051551","anchor_url":"https://secwatch.observer/filing/0000950170-24-051551#claim-95667f662e27ea0ac28078c273e3fe0661ee0464","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1136869/000095017024051551/0000950170-24-051551-index.htm"},{"fact_type":"earnings_release","fact_key":"c8b4b195627d71c54d52bb610db1b67aa9c3c800","cik":1136869,"ticker":"ZBH","company_name":"ZIMMER BIOMET HOLDINGS, INC.","filed_at":"2024-02-08T23:59:59+00:00","payload":{"eps_text":"Adjusted Diluted EPS $8.00 - $8.15","guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"year ending December 31, 2024","report_date":"2024-02-08","result_type":"guidance_update","revenue_text":"2024 Reported Revenue Change 4.5% - 5.5%"},"claim":"ZIMMER BIOMET HOLDINGS, INC. reported year ending December 31, 2024 results: revenue 2024 Reported Revenue Change 4.5% - 5.5%, EPS Adjusted Diluted EPS $8.00 - $8.15. Guidance reaffirmed.","evidence_excerpt":"The Company is providing the following full-year 2024 financial guidance: Projected Year Ending December 31, 2024 2024 Reported Revenue Change 4.5% - 5.5%","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0000950170-24-012530","anchor_url":"https://secwatch.observer/filing/0000950170-24-012530#claim-c8b4b195627d71c54d52bb610db1b67aa9c3c800","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1136869/000095017024012530/0000950170-24-012530-index.htm"},{"fact_type":"earnings_release","fact_key":"e807e7e8dc38ae0e048263835cabaf10a0fc1d5c","cik":1136869,"ticker":"ZBH","company_name":"ZIMMER BIOMET HOLDINGS, INC.","filed_at":"2024-02-08T23:59:59+00:00","payload":{"eps_text":"Diluted earnings per share were $2.01 for the fourth quarter; Full-year diluted earnings per share were $4.88","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"Net earnings for the fourth quarter were $419.2 million; For the full year, net earnings were $1.024 billion","period_text":"quarter and year ended December 31, 2023","report_date":"2024-02-08","result_type":"reported_results","revenue_text":"Fourth quarter net sales of $1.940 billion; Full-year net sales of $7.394 billion"},"claim":"ZIMMER BIOMET HOLDINGS, INC. reported quarter and year ended December 31, 2023 results: revenue Fourth quarter net sales of $1.940 billion; Full-year net sales of $7.394 billion, net income Net earnings for the fourth quarter were $419.2 million; For the full year, net earnings were $1.024 billion, EPS Diluted earnings per share were $2.01 for the fourth quarter; Full-year diluted earnings per share were $4.88.","evidence_excerpt":"heather.zoumaslubeski@zimmerbiomet.com zach.weiner@zimmerbiomet.com Zimmer Biomet Announces Fourth Quarter and Full-Year 2023 Financial Results • Fourth quarter net sales of $1.940 billion increased 6.3% and 6.1% on a constant currency 1 basis • Fourth quarter diluted earnings per share were $2.01; adjusted 1 diluted earnings per share were $2.20 • Full-year net","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0000950170-24-012530","anchor_url":"https://secwatch.observer/filing/0000950170-24-012530#claim-e807e7e8dc38ae0e048263835cabaf10a0fc1d5c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1136869/000095017024012530/0000950170-24-012530-index.htm"},{"fact_type":"executive_change","fact_key":"ec6e3ce227","cik":1136869,"ticker":"ZBH","company_name":"ZIMMER BIOMET HOLDINGS, INC.","filed_at":"2024-01-05T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-01-05","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Louis A. Shapiro was appointed as Director at ZIMMER BIOMET HOLDINGS, INC..","evidence_excerpt":"On January 5, 2024, the Board of Directors (the “Board”) of Zimmer Biomet Holdings, Inc. (the “Company”), upon the recommendation of the Corporate Governance Committee, increased the size of the Board from ten members to eleven members and appointed Louis A. Shapiro to fill the resulting vacancy, with a term to expire at the Company’s 2024 annual meeting of shareholders.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-24-002878","anchor_url":"https://secwatch.observer/filing/0001193125-24-002878#claim-ec6e3ce227","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1136869/000119312524002878/0001193125-24-002878-index.htm"},{"fact_type":"debt_financing","fact_key":"27e74b7f8f680ab9efeaa02e4167134fa23cda05","cik":1136869,"ticker":"ZBH","company_name":"ZIMMER BIOMET HOLDINGS, INC.","filed_at":"2023-12-01T23:59:59+00:00","payload":{"counterparty":"Barclays Capital Inc., Goldman Sachs & Co. LLC, Mizuho Securities USA LLC and Morgan Stanley & Co. LLC","effective_date":"2023-11-28","event":"incurrence","instrument_type":"senior_notes","interest_rate_text":"5.350% per annum","item_codes_triggered":["2.03"],"maturity_text":"December 1, 2028","principal_text":"$500.0 million aggregate principal amount"},"claim":"ZIMMER BIOMET HOLDINGS, INC. incurred senior notes of $500.0 million aggregate principal amount with Barclays Capital Inc., Goldman Sachs & Co. LLC, Mizuho Securities USA LLC and Morgan Stanley & Co. LLC at 5.350% per annum maturing December 1, 2028.","evidence_excerpt":"USA LLC and Morgan Stanley & Co. LLC, as representatives of the underwriters named therein (collectively, the “Underwriters”), in connection with the public offering of $500.0 million aggregate principal amount of the Company’s 5.350% Note due 2028 (the “Notes”). The issuance of the Notes was completed on December 1, 2023. The Underwriting Agreement contains","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-23-287490","anchor_url":"https://secwatch.observer/filing/0001193125-23-287490#claim-27e74b7f8f680ab9efeaa02e4167134fa23cda05","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1136869/000119312523287490/0001193125-23-287490-index.htm"},{"fact_type":"material_agreement","fact_key":"d0b5b1407ee7016ac544a0154b3ac161d27c3b3e","cik":1136869,"ticker":"ZBH","company_name":"ZIMMER BIOMET HOLDINGS, INC.","filed_at":"2023-12-01T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Ninth Supplemental Indenture","agreement_type":"notes_offering","counterparty":"Computershare Trust Company, N.A.","effective_date":"2023-12-01","item_codes_triggered":["1.01"],"value_text":null},"claim":"ZIMMER BIOMET HOLDINGS, INC. entered into Ninth Supplemental Indenture with Computershare Trust Company, N.A. (effective 2023-12-01).","evidence_excerpt":"The Notes were issued pursuant to the Ninth Supplemental Indenture dated as of December 1, 2023 (the “Supplemental Indenture”), to the Company’s Indenture (the “Base Indenture”) dated as of November 17, 2009, between the Company and Computershare Trust Company, N.A., as successor to Wells Fargo Bank, National Association, as trustee.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-23-287490","anchor_url":"https://secwatch.observer/filing/0001193125-23-287490#claim-d0b5b1407ee7016ac544a0154b3ac161d27c3b3e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1136869/000119312523287490/0001193125-23-287490-index.htm"},{"fact_type":"material_agreement","fact_key":"ac8190c17629f5c5df5bfb835f33654f08283d18","cik":1136869,"ticker":"ZBH","company_name":"ZIMMER BIOMET HOLDINGS, INC.","filed_at":"2023-12-01T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Underwriting Agreement","agreement_type":"underwriting","counterparty":"Barclays Capital Inc., Goldman Sachs & Co. LLC, Mizuho Securities USA LLC and Morgan Stanley & Co. LLC","effective_date":"2023-11-28","item_codes_triggered":["1.01"],"value_text":"$500.0 million aggregate principal amount"},"claim":"ZIMMER BIOMET HOLDINGS, INC. entered into Underwriting Agreement with Barclays Capital Inc., Goldman Sachs & Co. LLC, Mizuho Securities USA LLC and Morgan Stanley & Co. LLC valued at $500.0 million aggregate principal amount (effective 2023-11-28).","evidence_excerpt":"On November 28, 2023, Zimmer Biomet Holdings, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Barclays Capital Inc., Goldman Sachs & Co. LLC, Mizuho Securities USA LLC and Morgan Stanley & Co. LLC, as representatives of the underwriters named therein (collectively, the “Underwriters”), in connection with the public offering of $500.0 million aggregate principal amount of the Company’s 5.350% Note due 2028 (the “Notes”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-23-287490","anchor_url":"https://secwatch.observer/filing/0001193125-23-287490#claim-ac8190c17629f5c5df5bfb835f33654f08283d18","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1136869/000119312523287490/0001193125-23-287490-index.htm"},{"fact_type":"earnings_release","fact_key":"52a5898746c14f4c3465c6ce8d0af488dccb0eb3","cik":1136869,"ticker":"ZBH","company_name":"ZIMMER BIOMET HOLDINGS, INC.","filed_at":"2023-11-07T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the quarter ended September 30, 2023","report_date":"2023-11-07","result_type":"reported_results","revenue_text":null},"claim":"ZIMMER BIOMET HOLDINGS, INC. reported financial results for the quarter ended September 30, 2023.","evidence_excerpt":"On November 7, 2023, Zimmer Biomet Holdings, Inc. (the “Company”) issued a press release reporting its financial results for the quarter ended September 30, 2023.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-23-059736","anchor_url":"https://secwatch.observer/filing/0000950170-23-059736#claim-52a5898746c14f4c3465c6ce8d0af488dccb0eb3","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1136869/000095017023059736/0000950170-23-059736-index.htm"},{"fact_type":"executive_change","fact_key":"c7a8d4ee23","cik":1136869,"ticker":"ZBH","company_name":"ZIMMER BIOMET HOLDINGS, INC.","filed_at":"2023-08-22T23:59:59+00:00","payload":{"action":"appointed","action_category":"role_change","departure_tone":"not_applicable","effective_date":"2023-08-22","interim":false,"role":"Chief Financial Officer and Executive Vice President – Finance, Operations and Supply Chain","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Suketu Upadhyay was appointed as Chief Financial Officer and Executive Vice President – Finance, Operations and Supply Chain at ZIMMER BIOMET HOLDINGS, INC..","evidence_excerpt":"Additionally, effective August 22, 2023, Suketu Upadhyay has been appointed to the newly-created position of Chief Financial Officer and Executive Vice President – Finance, Operations and Supply Chain.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-23-217504","anchor_url":"https://secwatch.observer/filing/0001193125-23-217504#claim-c7a8d4ee23","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1136869/000119312523217504/0001193125-23-217504-index.htm"},{"fact_type":"executive_change","fact_key":"a62d55b3a6","cik":1136869,"ticker":"ZBH","company_name":"ZIMMER BIOMET HOLDINGS, INC.","filed_at":"2023-08-22T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2023-08-22","interim":false,"role":"Chairman of the Board","role_category":"chair","successor_name":null,"successor_named":false},"claim":"Christopher B. Begley was appointed as Chairman of the Board at ZIMMER BIOMET HOLDINGS, INC..","evidence_excerpt":"Effective August 22, 2023, the Board appointed Christopher B. Begley, who has been a director of the Company since 2012 and the Lead Independent Director since May 2021, to be the Chairman of the Board.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-23-217504","anchor_url":"https://secwatch.observer/filing/0001193125-23-217504#claim-a62d55b3a6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1136869/000119312523217504/0001193125-23-217504-index.htm"},{"fact_type":"executive_change","fact_key":"c13a9738f1","cik":1136869,"ticker":"ZBH","company_name":"ZIMMER BIOMET HOLDINGS, INC.","filed_at":"2023-08-22T23:59:59+00:00","payload":{"action":"elected","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2023-08-22","interim":false,"role":"Member of the Board of Directors","role_category":"director","successor_name":null,"successor_named":false},"claim":"Ivan Tornos was elected as Member of the Board of Directors at ZIMMER BIOMET HOLDINGS, INC..","evidence_excerpt":"Effective August 22, 2023, the Board appointed Ivan Tornos the Company’s President and Chief Executive Officer, and elected Mr. Tornos a member of the Board of Directors to fill the vacancy resulting from Mr. Hanson’s departure from the Board.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-23-217504","anchor_url":"https://secwatch.observer/filing/0001193125-23-217504#claim-c13a9738f1","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1136869/000119312523217504/0001193125-23-217504-index.htm"},{"fact_type":"executive_change","fact_key":"bbb98727a8","cik":1136869,"ticker":"ZBH","company_name":"ZIMMER BIOMET HOLDINGS, INC.","filed_at":"2023-08-22T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2023-08-22","interim":false,"role":"President and Chief Executive Officer","role_category":"ceo","successor_name":null,"successor_named":false},"claim":"Ivan Tornos was appointed as President and Chief Executive Officer at ZIMMER BIOMET HOLDINGS, INC..","evidence_excerpt":"Effective August 22, 2023, the Board appointed Ivan Tornos the Company’s President and Chief Executive Officer, and elected Mr. Tornos a member of the Board of Directors to fill the vacancy resulting from Mr. Hanson’s departure from the Board.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-23-217504","anchor_url":"https://secwatch.observer/filing/0001193125-23-217504#claim-bbb98727a8","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1136869/000119312523217504/0001193125-23-217504-index.htm"},{"fact_type":"executive_change","fact_key":"6b16204d3d","cik":1136869,"ticker":"ZBH","company_name":"ZIMMER BIOMET HOLDINGS, INC.","filed_at":"2023-08-22T23:59:59+00:00","payload":{"action":"stepped down","action_category":"departure","departure_tone":"routine","effective_date":"2023-08-22","interim":false,"role":"Chairman of the Board, President and Chief Executive Officer","role_category":"ceo","successor_name":"Ivan Tornos","successor_named":true},"claim":"Bryan C. Hanson departed as Chairman of the Board, President and Chief Executive Officer at ZIMMER BIOMET HOLDINGS, INC..","evidence_excerpt":"On August 17, 2023, Bryan C. Hanson notified the Company that he planned to step down as Chairman of the Board, President and Chief Executive Officer of the Company and as a member of the Company’s Board, all effective as of August 22, 2023.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-23-217504","anchor_url":"https://secwatch.observer/filing/0001193125-23-217504#claim-6b16204d3d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1136869/000119312523217504/0001193125-23-217504-index.htm"},{"fact_type":"earnings_release","fact_key":"1294259f7074e9f5d802ec5a619be4b4cdd0bf4b","cik":1136869,"ticker":"ZBH","company_name":"ZIMMER BIOMET HOLDINGS, INC.","filed_at":"2023-08-01T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the quarter ended June 30, 2023","report_date":"2023-08-01","result_type":"reported_results","revenue_text":null},"claim":"ZIMMER BIOMET HOLDINGS, INC. reported financial results for the quarter ended June 30, 2023.","evidence_excerpt":"On August 1, 2023, Zimmer Biomet Holdings, Inc. (the “Company”) issued a press release reporting its financial results for the quarter ended June 30, 2023.","confidence":0.4,"filing_url":"https://secwatch.observer/filing/0000950170-23-036153","anchor_url":"https://secwatch.observer/filing/0000950170-23-036153#claim-1294259f7074e9f5d802ec5a619be4b4cdd0bf4b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1136869/000095017023036153/0000950170-23-036153-index.htm"},{"fact_type":"debt_financing","fact_key":"4df5db8dfd5888379e6026af070a46a695062fe2","cik":1136869,"ticker":"ZBH","company_name":"ZIMMER BIOMET HOLDINGS, INC.","filed_at":"2023-07-10T23:59:59+00:00","payload":{"counterparty":"JPMorgan Chase Bank, N.A.","effective_date":"2023-07-07","event":"incurrence","instrument_type":"revolving_credit","interest_rate_text":"adjusted Term SOFR plus an applicable margin","item_codes_triggered":["2.03"],"maturity_text":"July 5, 2024","principal_text":"$1.0 billion"},"claim":"ZIMMER BIOMET HOLDINGS, INC. incurred revolving credit of $1.0 billion with JPMorgan Chase Bank, N.A. at adjusted Term SOFR plus an applicable margin maturing July 5, 2024.","evidence_excerpt":"The 364-Day Revolving Credit Agreement, dated as of July 7, 2023, among the Company, the lenders party thereto and JPMorgan Chase Bank, N.A., as administrative agent (the “364-Day Credit Agreement”), is an unsecured revolving credit facility in the principal amount of $1.0 billion (the “364-Day Revolving Facility”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-23-184743","anchor_url":"https://secwatch.observer/filing/0001193125-23-184743#claim-4df5db8dfd5888379e6026af070a46a695062fe2","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1136869/000119312523184743/0001193125-23-184743-index.htm"},{"fact_type":"debt_financing","fact_key":"959ebdfac48175e30cad3d0c5bfd05b0cb0a97a1","cik":1136869,"ticker":"ZBH","company_name":"ZIMMER BIOMET HOLDINGS, INC.","filed_at":"2023-07-10T23:59:59+00:00","payload":{"counterparty":"JPMorgan Chase Bank, N.A.","effective_date":"2023-07-07","event":"incurrence","instrument_type":"revolving_credit","interest_rate_text":"adjusted Term SOFR plus an applicable margin","item_codes_triggered":["2.03"],"maturity_text":"July 7, 2028","principal_text":"$1.5 billion"},"claim":"ZIMMER BIOMET HOLDINGS, INC. incurred revolving credit of $1.5 billion with JPMorgan Chase Bank, N.A. at adjusted Term SOFR plus an applicable margin maturing July 7, 2028.","evidence_excerpt":"On July 7, 2023, Zimmer Biomet Holdings, Inc. (the “Company”) entered into a new five-year revolving credit agreement and a new 364-day revolving credit agreement, as described below. The Five-Year Revolving Credit Agreement, dated as of July 7, 2023, among the Company, the lenders party thereto and JPMorgan Chase Bank, N.A., as administrative agent (the “Five-Year Credit Agreement”), is a five-year unsecured revolving facility of $1.5 billion (the “Five-Year Revolving Facility”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-23-184743","anchor_url":"https://secwatch.observer/filing/0001193125-23-184743#claim-959ebdfac48175e30cad3d0c5bfd05b0cb0a97a1","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1136869/000119312523184743/0001193125-23-184743-index.htm"},{"fact_type":"material_agreement","fact_key":"486f4e77644a578c98743b6375d6a22fbe844d4a","cik":1136869,"ticker":"ZBH","company_name":"ZIMMER BIOMET HOLDINGS, INC.","filed_at":"2023-07-10T23:59:59+00:00","payload":{"action":"termination","agreement_name":"2022 364-Day Credit Agreement","agreement_type":"credit_facility","counterparty":"JPMorgan Chase Bank, N.A., as administrative agent","effective_date":"2023-07-07","item_codes_triggered":["1.02"],"value_text":null},"claim":"ZIMMER BIOMET HOLDINGS, INC. terminated 2022 364-Day Credit Agreement with JPMorgan Chase Bank, N.A., as administrative agent (effective 2023-07-07).","evidence_excerpt":"The Five-Year Revolving Credit Agreement, dated as of July 7, 2023, among the Company, the lenders party thereto and JPMorgan Chase Bank, N.A., as administrative agent (the “Five-Year Credit Agreement”), is a five-year unsecured revolving facility of $1.5 billion (the “Five-Year Revolving Facility”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-23-184743","anchor_url":"https://secwatch.observer/filing/0001193125-23-184743#claim-486f4e77644a578c98743b6375d6a22fbe844d4a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1136869/000119312523184743/0001193125-23-184743-index.htm"},{"fact_type":"material_agreement","fact_key":"421bbf0f9ebaa59f74af95b175e2444917f4da5d","cik":1136869,"ticker":"ZBH","company_name":"ZIMMER BIOMET HOLDINGS, INC.","filed_at":"2023-07-10T23:59:59+00:00","payload":{"action":"termination","agreement_name":"2022 Five-Year Credit Agreement","agreement_type":"credit_facility","counterparty":"JPMorgan Chase Bank, N.A., as administrative agent","effective_date":"2023-07-07","item_codes_triggered":["1.02"],"value_text":"$520.0 million"},"claim":"ZIMMER BIOMET HOLDINGS, INC. terminated 2022 Five-Year Credit Agreement with JPMorgan Chase Bank, N.A., as administrative agent valued at $520.0 million (effective 2023-07-07).","evidence_excerpt":"There was $520.0 million in aggregate outstanding borrowings under the 2022 Five-Year Credit Agreement at the time it was terminated, which borrowings were repaid through borrowings on July 7, 2023 in the same amounts and on the same terms under the Five-Year Credit Agreement.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-23-184743","anchor_url":"https://secwatch.observer/filing/0001193125-23-184743#claim-421bbf0f9ebaa59f74af95b175e2444917f4da5d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1136869/000119312523184743/0001193125-23-184743-index.htm"},{"fact_type":"material_agreement","fact_key":"5829f7de4dbb741e8e3f6201ea4d7ec255f70fac","cik":1136869,"ticker":"ZBH","company_name":"ZIMMER BIOMET HOLDINGS, INC.","filed_at":"2023-07-10T23:59:59+00:00","payload":{"action":"entry","agreement_name":"364-Day Credit Agreement","agreement_type":"credit_facility","counterparty":"JPMorgan Chase Bank, N.A., as administrative agent","effective_date":"2023-07-07","item_codes_triggered":["1.01"],"value_text":"$1.0 billion"},"claim":"ZIMMER BIOMET HOLDINGS, INC. entered into 364-Day Credit Agreement with JPMorgan Chase Bank, N.A., as administrative agent valued at $1.0 billion (effective 2023-07-07).","evidence_excerpt":"The 364-Day Revolving Credit Agreement, dated as of July 7, 2023, among the Company, the lenders party thereto and JPMorgan Chase Bank, N.A., as administrative agent (the “364-Day Credit Agreement”), is an unsecured revolving credit facility in the principal amount of $1.0 billion (the “364-Day Revolving Facility”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-23-184743","anchor_url":"https://secwatch.observer/filing/0001193125-23-184743#claim-5829f7de4dbb741e8e3f6201ea4d7ec255f70fac","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1136869/000119312523184743/0001193125-23-184743-index.htm"},{"fact_type":"material_agreement","fact_key":"22746f46c7f960739cd689c0788351b73f787a0c","cik":1136869,"ticker":"ZBH","company_name":"ZIMMER BIOMET HOLDINGS, INC.","filed_at":"2023-07-10T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Five-Year Credit Agreement","agreement_type":"credit_facility","counterparty":"JPMorgan Chase Bank, N.A., as administrative agent","effective_date":"2023-07-07","item_codes_triggered":["1.01"],"value_text":"$1.5 billion"},"claim":"ZIMMER BIOMET HOLDINGS, INC. entered into Five-Year Credit Agreement with JPMorgan Chase Bank, N.A., as administrative agent valued at $1.5 billion (effective 2023-07-07).","evidence_excerpt":"The Five-Year Revolving Credit Agreement, dated as of July 7, 2023, among the Company, the lenders party thereto and JPMorgan Chase Bank, N.A., as administrative agent (the “Five-Year Credit Agreement”), is a five-year unsecured revolving facility of $1.5 billion (the “Five-Year Revolving Facility”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-23-184743","anchor_url":"https://secwatch.observer/filing/0001193125-23-184743#claim-22746f46c7f960739cd689c0788351b73f787a0c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1136869/000119312523184743/0001193125-23-184743-index.htm"},{"fact_type":"shareholder_vote","fact_key":"9502c5521aea008289763d9895f1ddf7aa39b577","cik":1136869,"ticker":"ZBH","company_name":"ZIMMER BIOMET HOLDINGS, INC.","filed_at":"2023-05-16T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-05-12","outcome":"passed","proposal_text":"Advisory vote on frequency of future say-on-pay votes","proposal_type":"say_on_pay_frequency","results":[{"broker_non_votes":"14,759,329","subject":"One Year","votes_abstain":null,"votes_against":null,"votes_for":"168,589,917","votes_withheld":null},{"broker_non_votes":"14,759,329","subject":"Two Years","votes_abstain":null,"votes_against":null,"votes_for":"209,817","votes_withheld":null},{"broker_non_votes":"14,759,329","subject":"Three Years","votes_abstain":null,"votes_against":null,"votes_for":"2,185,659","votes_withheld":null},{"broker_non_votes":"14,759,329","subject":"Abstain","votes_abstain":null,"votes_against":null,"votes_for":"237,765","votes_withheld":null}]},"claim":"ZIMMER BIOMET HOLDINGS, INC. shareholders approved Advisory vote on frequency of future say-on-pay votes at the 2023-05-12 meeting.","evidence_excerpt":"Proposal 4 – Advisory Vote on the Frequency of Future Say on Pay Votes One Year Two Years Three Years Abstain Broker Non-Votes 168,589,917 209,817 2,185,659 237,765 14,759,329","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-23-146173","anchor_url":"https://secwatch.observer/filing/0001193125-23-146173#claim-9502c5521aea008289763d9895f1ddf7aa39b577","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1136869/000119312523146173/0001193125-23-146173-index.htm"},{"fact_type":"shareholder_vote","fact_key":"f1a94343f0e1e3ef91cf4583e23dee725eb4f91d","cik":1136869,"ticker":"ZBH","company_name":"ZIMMER BIOMET HOLDINGS, INC.","filed_at":"2023-05-16T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-05-12","outcome":"passed","proposal_text":"Advisory vote to approve named executive officer compensation","proposal_type":"say_on_pay","results":[{"broker_non_votes":"14,759,329","subject":null,"votes_abstain":"317,041","votes_against":"16,581,269","votes_for":"154,324,848","votes_withheld":null}]},"claim":"ZIMMER BIOMET HOLDINGS, INC. shareholders approved Advisory vote to approve named executive officer compensation at the 2023-05-12 meeting.","evidence_excerpt":"Proposal 3 – Advisory Vote to Approve Named Executive Officer Compensation (“Say on Pay”) For Against Abstain Broker Non-Votes 154,324,848 16,581,269 317,041 14,759,329","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-23-146173","anchor_url":"https://secwatch.observer/filing/0001193125-23-146173#claim-f1a94343f0e1e3ef91cf4583e23dee725eb4f91d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1136869/000119312523146173/0001193125-23-146173-index.htm"},{"fact_type":"shareholder_vote","fact_key":"12c9572caa8054f590872c35b45b99e0326234e7","cik":1136869,"ticker":"ZBH","company_name":"ZIMMER BIOMET HOLDINGS, INC.","filed_at":"2023-05-16T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-05-12","outcome":"passed","proposal_text":"Ratification of the appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for 2023","proposal_type":"auditor_ratification","results":[{"broker_non_votes":"0","subject":null,"votes_abstain":"229,050","votes_against":"6,107,827","votes_for":"179,645,610","votes_withheld":null}]},"claim":"ZIMMER BIOMET HOLDINGS, INC. shareholders approved Ratification of the appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for 2023 at the 2023-05-12 meeting.","evidence_excerpt":"Proposal 2 – Ratification of the Appointment of the Independent Registered Public Accounting Firm For Against Abstain Broker Non-Votes 179,645,610 6,107,827 229,050 0","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-23-146173","anchor_url":"https://secwatch.observer/filing/0001193125-23-146173#claim-12c9572caa8054f590872c35b45b99e0326234e7","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1136869/000119312523146173/0001193125-23-146173-index.htm"},{"fact_type":"shareholder_vote","fact_key":"d8abfa58e144d58a257a7a4c0efc704d659eff60","cik":1136869,"ticker":"ZBH","company_name":"ZIMMER BIOMET HOLDINGS, INC.","filed_at":"2023-05-16T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-05-12","outcome":"passed","proposal_text":"Election of ten directors for one-year terms ending at the 2024 annual meeting","proposal_type":"director_election","results":[{"broker_non_votes":"14,759,329","subject":"Christopher B. Begley","votes_abstain":"263,451","votes_against":"4,050,882","votes_for":"166,908,825","votes_withheld":null},{"broker_non_votes":"14,759,329","subject":"Betsy J. Bernard","votes_abstain":"238,098","votes_against":"6,968,137","votes_for":"164,016,923","votes_withheld":null},{"broker_non_votes":"14,759,329","subject":"Michael J. Farrell","votes_abstain":"245,007","votes_against":"2,483,935","votes_for":"168,494,216","votes_withheld":null},{"broker_non_votes":"14,759,329","subject":"Robert A. Hagemann","votes_abstain":"263,819","votes_against":"9,763,336","votes_for":"161,196,003","votes_withheld":null},{"broker_non_votes":"14,759,329","subject":"Bryan C. Hanson","votes_abstain":"567,323","votes_against":"7,752,853","votes_for":"162,902,982","votes_withheld":null},{"broker_non_votes":"14,759,329","subject":"Arthur J. Higgins","votes_abstain":"248,440","votes_against":"9,290,615","votes_for":"161,684,103","votes_withheld":null},{"broker_non_votes":"14,759,329","subject":"Maria Teresa Hilado","votes_abstain":"227,614","votes_against":"1,693,759","votes_for":"169,301,785","votes_withheld":null},{"broker_non_votes":"14,759,329","subject":"Syed Jafry","votes_abstain":"248,049","votes_against":"2,405,034","votes_for":"168,570,075","votes_withheld":null},{"broker_non_votes":"14,759,329","subject":"Sreelakshmi Kolli","votes_abstain":"245,631","votes_against":"844,303","votes_for":"170,133,224","votes_withheld":null},{"broker_non_votes":"14,759,329","subject":"Michael W. Michelson","votes_abstain":"245,714","votes_against":"2,419,477","votes_for":"168,557,967","votes_withheld":null}]},"claim":"ZIMMER BIOMET HOLDINGS, INC. shareholders approved Election of ten directors for one-year terms ending at the 2024 annual meeting at the 2023-05-12 meeting.","evidence_excerpt":"Proposal 1 – Election of Directors Nominee For Against Abstain Broker Non-Votes Christopher B. Begley 166,908,825 4,050,882 263,451 14,759,329 Betsy J. Bernard 164,016,923 6,968,137 238,098 14,759,329 Michael J. Farrell 168,494,216 2,483,935 245,007 14,759,329 Robert A. Hagemann 161,196,003 9,763,336 263,819 14,759,329 Bryan C. Hanson 162,902,982 7,752,853 567,323 14,759,329 Arthur J. Higgins 161,684,103 9,290,615 248,440 14,759,329 Maria Teresa Hilado 169,301,785 1,693,759 227,614 14,759,329 Syed Jafry 168,570,075 2,405,034 248,049 14,759,329 Sreelakshmi Kolli 170,133,224 844,303 245,631 14,759,329 Michael W. Michelson 168,557,967 2,419,477 245,714 14,759,329","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-23-146173","anchor_url":"https://secwatch.observer/filing/0001193125-23-146173#claim-d8abfa58e144d58a257a7a4c0efc704d659eff60","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1136869/000119312523146173/0001193125-23-146173-index.htm"},{"fact_type":"earnings_release","fact_key":"b15dc276af8f61be2fb4d8dbe12b5c9639aa8d11","cik":1136869,"ticker":"ZBH","company_name":"ZIMMER BIOMET HOLDINGS, INC.","filed_at":"2023-05-02T23:59:59+00:00","payload":{"eps_text":"$7.40 - $7.50","guidance_signal":"raised","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"full-year 2023","report_date":"2023-05-02","result_type":"guidance_update","revenue_text":null},"claim":"ZIMMER BIOMET HOLDINGS, INC. reported full-year 2023 results: EPS $7.40 - $7.50. Guidance raised.","evidence_excerpt":"Projected Year Ending December 31, 2023 Previous Guidance Updated Guidance 2023 Reported Revenue Change 1.5% - 3.5% 5.0% - 6.0% Foreign Currency Exchange Impact (1.5)% (1.0)% Adjusted Diluted EPS (1) $6.95 - $7.15 $7.40 - $7.50","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-23-016423","anchor_url":"https://secwatch.observer/filing/0000950170-23-016423#claim-b15dc276af8f61be2fb4d8dbe12b5c9639aa8d11","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1136869/000095017023016423/0000950170-23-016423-index.htm"},{"fact_type":"earnings_release","fact_key":"9be9e94e5275afc8f5241ec3062c59175bda8e10","cik":1136869,"ticker":"ZBH","company_name":"ZIMMER BIOMET HOLDINGS, INC.","filed_at":"2023-05-02T23:59:59+00:00","payload":{"eps_text":"$1.11","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$232.5 million","period_text":"first quarter ended March 31, 2023","report_date":"2023-05-02","result_type":"reported_results","revenue_text":"$1.831 billion"},"claim":"ZIMMER BIOMET HOLDINGS, INC. reported first quarter ended March 31, 2023 results: revenue $1.831 billion, net income $232.5 million, EPS $1.11.","evidence_excerpt":"The Company reported first quarter net sales of $1.831 billion, an increase of 10.1% over the prior year period, and an increase of 13.2% on a constant currency 1 basis. Net earnings for the first quarter were $232.5 million, or $396.8 million on an adjusted 1 basis. Diluted earnings per share were $1.11 for the first quarter, and adjusted 1 diluted earnings per share were $1.89.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-23-016423","anchor_url":"https://secwatch.observer/filing/0000950170-23-016423#claim-9be9e94e5275afc8f5241ec3062c59175bda8e10","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1136869/000095017023016423/0000950170-23-016423-index.htm"},{"fact_type":"earnings_release","fact_key":"f95a64b0a7afc9533ed8810ef59a596d6bbe3613","cik":1136869,"ticker":"ZBH","company_name":"ZIMMER BIOMET HOLDINGS, INC.","filed_at":"2023-02-03T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the quarter and year ended December 31, 2022","report_date":"2023-02-03","result_type":"reported_results","revenue_text":null},"claim":"ZIMMER BIOMET HOLDINGS, INC. reported financial results for the quarter and year ended December 31, 2022.","evidence_excerpt":"On February 3, 2023, Zimmer Biomet Holdings, Inc. (the “Company”) issued a press release reporting its financial results for the quarter and year ended December 31, 2022.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-23-001740","anchor_url":"https://secwatch.observer/filing/0000950170-23-001740#claim-f95a64b0a7afc9533ed8810ef59a596d6bbe3613","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1136869/000095017023001740/0000950170-23-001740-index.htm"},{"fact_type":"governance_change","fact_key":"64e507fc6ecfc0e2d0676cdbe6052caf34ffa3bd","cik":1136869,"ticker":"ZBH","company_name":"ZIMMER BIOMET HOLDINGS, INC.","filed_at":"2022-12-14T23:59:59+00:00","payload":{"change_type":"bylaw_amendment","effective_date":"2022-12-14","item_codes_triggered":["5.03"],"summary_text":"Amended and restated the bylaws to implement procedural mechanisms related to stockholder nominations of directors under Rule 14a-19, including certification requirements, nullification of nominations for non-compliance, reservation of white proxy cards, and other technical changes."},"claim":"ZIMMER BIOMET HOLDINGS, INC.: Amended and restated the bylaws to implement procedural mechanisms related to stockholder nominations of directors under Rule 14a-19, including certification requirements, nullification of nominations for non-compliance, reservation of white proxy cards, and other technical changes (effective 2022-12-14).","evidence_excerpt":"On December 14, 2022, the Board of Directors of Zimmer Biomet Holdings, Inc. (“Zimmer Biomet” or the “Company”) amended and restated the Company’s Restated Bylaws (as so amended and restated, the “Bylaws”), primarily to implement certain procedural mechanisms related to stockholder nominations of directors under Rule 14a-19 (“Rule 14a-19”) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These amendments took immediate effect.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-22-304888","anchor_url":"https://secwatch.observer/filing/0001193125-22-304888#claim-64e507fc6ecfc0e2d0676cdbe6052caf34ffa3bd","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1136869/000119312522304888/0001193125-22-304888-index.htm"},{"fact_type":"earnings_release","fact_key":"af1fbefaf4b5723cdb01919f81769342819aa086","cik":1136869,"ticker":"ZBH","company_name":"ZIMMER BIOMET HOLDINGS, INC.","filed_at":"2022-11-02T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the quarter ended September 30, 2022","report_date":"2022-11-02","result_type":"reported_results","revenue_text":null},"claim":"ZIMMER BIOMET HOLDINGS, INC. reported financial results for the quarter ended September 30, 2022.","evidence_excerpt":"On November 2, 2022, Zimmer Biomet Holdings, Inc. (the “Company”) issued a press release reporting its financial results for the quarter ended September 30, 2022.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-22-020960","anchor_url":"https://secwatch.observer/filing/0000950170-22-020960#claim-af1fbefaf4b5723cdb01919f81769342819aa086","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1136869/000095017022020960/0000950170-22-020960-index.htm"},{"fact_type":"executive_change","fact_key":"b43ab701db","cik":1136869,"ticker":"ZBH","company_name":"ZIMMER BIOMET HOLDINGS, INC.","filed_at":"2022-05-16T23:59:59+00:00","payload":{"action":"continue","action_category":"role_change","departure_tone":"not_applicable","effective_date":"2022-05-16","interim":false,"role":"Vice President, Finance Integration","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Derek Davis changed role as Vice President, Finance Integration at ZIMMER BIOMET HOLDINGS, INC..","evidence_excerpt":"Derek Davis, who served as the Company’s Interim Controller and Chief Accounting Officer and had assumed the responsibilities of the Company’s principal accounting officer during the search process that led to Mr. Stellato’s hiring, will continue in his role as the Company’s Vice President, Finance Integration.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001193125-22-150863","anchor_url":"https://secwatch.observer/filing/0001193125-22-150863#claim-b43ab701db","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1136869/000119312522150863/0001193125-22-150863-index.htm"},{"fact_type":"executive_change","fact_key":"b7af0ed083","cik":1136869,"ticker":"ZBH","company_name":"ZIMMER BIOMET HOLDINGS, INC.","filed_at":"2022-05-16T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2022-05-16","interim":false,"role":"Vice President, Controller and Chief Accounting Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Paul Stellato was appointed as Vice President, Controller and Chief Accounting Officer at ZIMMER BIOMET HOLDINGS, INC..","evidence_excerpt":"Paul Stellato has been appointed Vice President, Controller and Chief Accounting Officer of the Company.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001193125-22-150863","anchor_url":"https://secwatch.observer/filing/0001193125-22-150863#claim-b7af0ed083","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1136869/000119312522150863/0001193125-22-150863-index.htm"},{"fact_type":"executive_change","fact_key":"968d3d36e3","cik":1136869,"ticker":"ZBH","company_name":"ZIMMER BIOMET HOLDINGS, INC.","filed_at":"2021-10-29T23:59:59+00:00","payload":{"action":"will serve as","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2021-11-26","interim":true,"role":"Interim Controller and Chief Accounting Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Derek Davis was appointed as Interim Controller and Chief Accounting Officer at ZIMMER BIOMET HOLDINGS, INC..","evidence_excerpt":"the Company has determined that Derek Davis, the Company’s Vice President, Finance Integration, will serve as the Interim Controller and Chief Accounting Officer, and principal accounting officer, of the Company, effective upon Ms. Nichol’s departure on November 26, 2021.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-21-313375","anchor_url":"https://secwatch.observer/filing/0001193125-21-313375#claim-968d3d36e3","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1136869/000119312521313375/0001193125-21-313375-index.htm"},{"fact_type":"executive_change","fact_key":"d4d79ae573","cik":1136869,"ticker":"ZBH","company_name":"ZIMMER BIOMET HOLDINGS, INC.","filed_at":"2021-10-29T23:59:59+00:00","payload":{"action":"will be departing","action_category":"departure","departure_tone":"routine","effective_date":"2021-11-26","interim":true,"role":"Vice President, Controller and Chief Accounting Officer","role_category":"other_named_officer","successor_name":"Derek Davis","successor_named":true},"claim":"Carrie Nichol departed as Vice President, Controller and Chief Accounting Officer at ZIMMER BIOMET HOLDINGS, INC..","evidence_excerpt":"On October 29, 2021, Zimmer Biomet Holdings, Inc. (the “Company”) announced that Carrie Nichol, the Vice President, Controller and Chief Accounting Officer, and the principal accounting officer, of the Company, will be departing from the Company effective November 26, 2021.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-21-313375","anchor_url":"https://secwatch.observer/filing/0001193125-21-313375#claim-d4d79ae573","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1136869/000119312521313375/0001193125-21-313375-index.htm"}]}